z-logo
open-access-imgOpen Access
Dengue virus-1 NS5 genetic variant associated with a severe clinical infection: Possible reduction of the innate immune response by inhibition of interferon type 1 and the Janus kinase-signal transducer and activator of transcription signaling pathway
Author(s) -
Ivï¿ ⁄ n DelgadoEnciso,
Uriel Lï¿ ⁄ pezLemus,
Jose ValcarcelGamiï¿ ⁄ o,
Iram P. RodríguezSánchez,
Salvador ValleReyes,
Margarita L. MartínezFierro,
Valery Melnikov,
Josï¿ ⁄ Guzmï¿ ⁄ nEsquivel,
Felipe VacaPaniagua,
Laura Leticia Valdez-Velázquez,
Luz M. Baltazar-Rodríguez,
Alejandro D. Soriano-Hernández,
B.A. Paz-Michel,
Francisco EspinozaGï¿ ⁄ mez
Publication year - 2018
Publication title -
international journal of molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.048
H-Index - 90
eISSN - 1791-244X
pISSN - 1107-3756
DOI - 10.3892/ijmm.2018.3395
Subject(s) - biology , dengue virus , janus kinase , virus , virology , dengue fever , interferon , innate immune system , immune system , in silico , stat protein , immunology , genetics , gene , signal transduction , stat3
Dengue virus (DENV) is currently considered as one of the most important mosquito-borne viral pathogens affecting humans. Genetic variations in viruses are likely to be a condition for more effective evasion of the immune system and resulting in severe clinical consequences. The DENV‑1 NS5 gene was sequenced to establish whether during an epidemic burst there were genetic variations of the virus and whether any variant was associated (through a case‑control design) with severe clinical behavior. A total of 31 patients positive for DENV‑1 were enrolled. Among the nucleotide differences between the sequences, only two generated amino acid changes. The variants 124Met/166Ser (amino acid positions according to the report GenBank AJL35015.1), were associated with a severe clinical course of the disease. Via in silico tests, it was identified that the variations generate changes in the protein probably affecting the function of type‑1 interferon, either at the level of its receptor or by interfering with the Janus kinase‑signal transducer and activator of transcription signaling pathway.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom